<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095858</url>
  </required_header>
  <id_info>
    <org_study_id>7110-005</org_study_id>
    <secondary_id>15-4789</secondary_id>
    <secondary_id>FD-OOPD-006089</secondary_id>
    <secondary_id>CD24Fc-005-CATHY</secondary_id>
    <secondary_id>MK-7110-005</secondary_id>
    <nct_id>NCT04095858</nct_id>
    <nct_alias>NCT04976699</nct_alias>
  </id_info>
  <brief_title>CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)</brief_title>
  <acronym>CATHY</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-versus-host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoImmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoImmune, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc&#xD;
      vs placebo with the standard GVHD prophylaxis of tacrolimus / methotrexate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens:&#xD;
      CD24Fc/tacrolimus / methotrexate (CD24Fc/Tac/MTX) versus placebo/tacrolimus / methotrexate&#xD;
      (placebo/Tac/MTX) in the setting of myeloablative conditioning (MAC), matched unrelated donor&#xD;
      (MUD) allogeneic hematopoietic stem cell transplantation in participants with acute leukemia&#xD;
      (AML/ALL) or myelodysplastic syndrome (MDS). The study agent, CD24Fc, will be administered&#xD;
      through IV infusion on days -1, 14, and 28 at the dose of 480mg, 240 mg and 240mg,&#xD;
      respectively. The placebo will be 100 ml normal saline intravenous (IV) solution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Reasons&#xD;
  </why_stopped>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Actual">November 5, 2021</completion_date>
  <primary_completion_date type="Actual">November 5, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>180 day grade III-IV acute GVHD free survival (AGFS)</measure>
    <time_frame>Up to 180 days after HCT</time_frame>
    <description>180 day grade III-IV acute GVHD free survival (AGFS) is a composite endpoint to determine the Grade III-IV AGFS in 180 days after HCT. The onset day of Grade III-IV aGVHD, or death of any cause, which comes the first, will be counted as the event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>OS is defined as the time of all-cause mortality after HCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>DFS is defined as the earlier of time of leukemia relapse, or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180 day grade II-IV acute GVHD free survival (AGFS)</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>180 day grade II-IV acute GVHD free survival (AGFS) is a composite endpoint to determine the Grade II-IV AGFS 180 days after HCT. The onset day of Grade II-IV aGVHD, or death of any cause, whichever comes the first, will be counted as the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180 day grade III-IV acute GVHD relapse-free survival (AGRFS)</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>180 day grade III-IV acute GVHD relapse-free survival (AGRFS) is a composite endpoint to determine the Grade III-IV AGRFS 180 days after HCT. The onset day of Grade III-IV aGRFS, relapse, or death of any cause, whichever comes first, will be counted as the event.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Acute Graft Versus Host Disease</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>CD24Fc Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD24Fc: IV infusion, 480 mg (day -1), 240 mg (day +14) and 240 mg (day +28); Tacrolimus: begin on day -3. IV [0.03 mg/kg/day] or by mouth (PO) [0.045 mg/kg/dose] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m^2/dose once daily on Day 1 after hematopoietic cell transplantation (HCT), and at a dose of 10 mg/m^2/dose on days 3, 6, and 11 after HCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Saline solution): 100 ml IV infusion, Day -1, Day 14, Day 28. Tacrolimus: begin on day -3. IV [0.03mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m^2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m^2/dose on days 3, 6, and 11 after HCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD24Fc</intervention_name>
    <description>IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.</description>
    <arm_group_label>CD24Fc Treatment</arm_group_label>
    <other_name>Human CD24 and human IgG Fc Fusion Protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion, 100 ml at Day -1, Day 14, and Day 28.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>IV, 15 mg/m^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.</description>
    <arm_group_label>CD24Fc Treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted</description>
    <arm_group_label>CD24Fc Treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A prospective participant for allogeneic HCT for a malignant hematologic disorder.&#xD;
&#xD;
          2. The donor and recipient must have a human leukocyte antigen (HLA)-8/8 allelic match at&#xD;
             the HLA-A, -B, -C, and - DRB1 loci. High-resolution typing is required for all alleles&#xD;
             for unmatched donors. Only matched unrelated donors are acceptable for this trial.&#xD;
&#xD;
          3. The following diagnoses are to be included:&#xD;
&#xD;
               1. Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) in first or&#xD;
                  second remission. Remission is defined as the absence of blasts in the peripheral&#xD;
                  circulation at the time of enrollment, &lt; 5% blasts in the bone marrow and absence&#xD;
                  of extramedullary disease including CNS involvement.&#xD;
&#xD;
               2. Myelodysplastic syndrome (MDS) with intermediate or high-risk International&#xD;
                  Prognostic Scoring System (IPSS) or equivalent Revised International Prognostic&#xD;
                  Scoring System (IPSS-R) score with &lt; 10% blasts in the bone marrow.&#xD;
&#xD;
          4. Males or non-pregnant, non-lactating females, â‰¥ 18 years of age. Note there is no&#xD;
             defined upper age limited, so long as deemed appropriate candidate for myeloablative&#xD;
             conditioning.&#xD;
&#xD;
          5. Karnofsky Performance Status &gt;70%.&#xD;
&#xD;
          6. Participants must have normal or near normal organ function as defined by their&#xD;
             treating institutions bone marrow transplant (BMT) program clinical practice&#xD;
             guidelines. In addition, for purposes of this protocol minimum organ function criteria&#xD;
             within 30 days of beginning conditioning include: Eligibility According to Pre HCT&#xD;
             Organ Function:&#xD;
&#xD;
               1. Total bilirubin â‰¤2.5 mg% (unless from Gilbert's disease or disease-related);&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase&#xD;
                  (SGOT))/ alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase&#xD;
                  (SGPT)) &lt;5.0 X institutional upper limit of normal;&#xD;
&#xD;
               3. Estimated or actual glomerular filtration rate (GFR)&gt;50 mL/min/1.73 m2 for&#xD;
                  participants with creatinine levels above institutional normal (GFR should be&#xD;
                  corrected for BSA);&#xD;
&#xD;
               4. Pulmonary Function Tests include diffusing capacity of the lungs for carbon&#xD;
                  monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital&#xD;
                  capacity (FVC)&gt; 50% DLCO should be corrected for hemoglobin;&#xD;
&#xD;
               5. Ejection Fraction &gt;50%;&#xD;
&#xD;
               6. Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) â‰¤ 5.&#xD;
&#xD;
             Item d and e may be assessed up to 10 weeks prior to the start of conditioning&#xD;
             therapy.&#xD;
&#xD;
          7. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          8. Women of child bearing potential and men must agree to use contraception prior to&#xD;
             study entry and through day 100 post HCT (hormonal or barrier method of birth control;&#xD;
             abstinence). Should a woman become pregnant or suspect she is pregnant while she or&#xD;
             her partner is on treatment in this study, she should inform her study physician&#xD;
             immediately. Men treated or enrolled on this protocol must also agree to use adequate&#xD;
             contraception prior to the study until day 100 post HCT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects may not have presence of active central nervous system (CNS) disease or&#xD;
             extramedullary disease.&#xD;
&#xD;
          2. Prior cytotoxic chemotherapy within 21 days from the initiation of HCT conditioning&#xD;
             (i.e. intensive induction / consolidation for AML). Note, certain low intensity&#xD;
             treatments not intended to induce remission but rather stabilize disease are&#xD;
             acceptable up to 24 hrs prior to initiation of HCT conditioning (i.e. Tyrosine Kinase&#xD;
             Inhibitor, sorafenib).&#xD;
&#xD;
          3. Cord blood and haploidentical donors are not eligible.&#xD;
&#xD;
          4. HLA-mismatch at the HLA-A, -B, -C, and - DRB1 loci. Note, HLA-DQ mismatches are&#xD;
             permissible.&#xD;
&#xD;
          5. Pregnant and nursing mothers are excluded from this study. This is because the risk to&#xD;
             the fetus is unknown.&#xD;
&#xD;
          6. Any physical or psychological condition that, in the opinion of the investigator,&#xD;
             would pose unacceptable risk to the participant or raise concern that the participant&#xD;
             would not comply with protocol procedures.&#xD;
&#xD;
          7. Uncontrolled infections. Participants still under therapy for presumed or proven&#xD;
             infection are eligible provided there is clear evidence (radiologic, clinical and/or&#xD;
             culture) that the infection is well controlled.&#xD;
&#xD;
          8. Participants seropositive or polymerase chain reaction (PCR) positive for the human&#xD;
             immunodeficiency virus (HIV). Participants with evidence of Hepatitis B or Hepatitis C&#xD;
             PCR positivity.&#xD;
&#xD;
          9. Prior HCT (allograft or prior autograft).&#xD;
&#xD;
         10. Use of T cell depletion either ex vivo or in vivo (i.e. anti-thymocyte globulin (ATG),&#xD;
             alemtuzumab) is prohibited.&#xD;
&#xD;
         11. Current or prior diagnosis of antecedent Myelofibrosis is excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope ( Site 0302)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center ( Site 0306)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State University Milton S. Hershey Medical Center ( Site 0304)</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania ( Site 0309)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

